Insider Transactions Reported by 16 Insiders of Revance Therapeutics, Inc.

Location
Nashville, TN

There are no Buy or Sell transactions made by insiders since 12 Mar 2025

Revance Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Aubrey Rankin Director $4,257,930 15 Mar 2022
Abhay Joshi COO, President of R&D $901,689 15 Mar 2022
Dustin S. Sjuts President $844,871 15 Mar 2024
Chris Nolet Director $0 04 Feb 2025
Angus C. Russell Director $0 04 Feb 2025
Jill Beraud Director $0 04 Feb 2025
Dwight Moxie Clo & Gc $0 04 Feb 2025
Julian S. Gangolli Director $0 04 Feb 2025
Mark J. Foley President & CEO, Director $0 04 Feb 2025
Tobin Schilke Cfo $0 04 Feb 2025
Olivia C. Ware Director $0 04 Feb 2025
Carey OConnor Kolaja Director $0 04 Feb 2025
Vlad Coric Director $0 04 Feb 2025
Erica Jordan Chief Commercial Officer $0 04 Feb 2025
David Hollander CMO & Global Therapeutics Lead $0 04 Feb 2025
Philip J. Vickers Director 04 May 2022

Recent Insider Transactions by Companies or Individuals for Revance Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.